Medical scans of a human brain

Our Pipeline

Creating a Roadmap for Innovation

We’re always looking forward to the next step: Delivering hope through tangible solutions for patients suffering from central nervous system (CNS) conditions.

By focusing on treatments for CNS conditions, we strive to meet the needs of patients by providing innovative solutions. Below is an overview of our pipeline.

AVP-786

Agitation in Alzheimer's Dementia (Global)
Phase 1
Phase 2
Phase 3
Registration
Phase 4

Description

The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with Alzheimer’s Dementia.

See our clinical trial

Negative Symptoms of Schizophrenia
Phase 1
Phase 2
Phase 3
Registration
Phase 4

Description

The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 as an adjunctive treatment compared to placebo in patients with schizophrenia who have negative symptoms.

See our clinical trial

Intermittent Explosive Disorder
Phase 1
Phase 2
Phase 3
Registration
Phase 4

Description

The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of patients with intermittent explosive disorder (IED).

Neurobehavioral Disinhibition in Traumatic Brain Injury
Phase 1
Phase 2
Phase 3
Registration
Phase 4

Description

The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation and irritability of patients with traumatic brain injury.

See our clinical trial

People who work here are really passionate about what they do. They believe in their work and they’re committed to ensure that we find the right answers to what we are working on. Everybody wants to challenge themselves.

Sanjay Dubé
Vice President, Clinical Development

MLR-AVN-US-0336-0220